FDA is extending the comment period for its proposed systematic process for post-market assessment of chemicals in foods, which it laid out in late September to mixed reviews from industry ...
With a Price to Earnings ratio of 36.05, which is 0.27x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback